tirzepatide in children LLY -0.60% today as Lilly's Mounjaro (tirzepatide), a GIP/GLP-1 dual receptor agonist, reduced A1C by an average of 2.2% a Phase 3 trial of and adolescents with type 2 diabetes tirzepatide adolescent obesity trial Efficacy

The most established, longest-track-record brand

Over weeks, that small daily calorie deficit produces 2 to 3% body weight loss

Reduced mitochondrial density and increased IRS-1 serine phosphorylation in muscle of insulin-resistant offspring of type 2 diabetic parents

This article explains how retatrutide works, summarises the key trial findings, reviews its safety profile, and contextualises what these early data mean for future obesity treatment in the UK

They are often prescribed when there is a shortage of branded drugs or when a patient needs a specific dosage not available in branded form

Unfortunately, there is a long waiting list for these medications through the NHS